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Studies of viral accessory genes have progressed in order to understand pathogenesis and 
develop effective therapeutics and vaccines. For human immunodeficiency virus type-1 (HIV-1), 
one such gene receiving special focus is vpr. Vpr has been implicated in dysregulation of host 
cellular events (including cell cycle arrest and apoptosis), infection of non-dividing cells, and 
increased viral replication in infected T cells. In simian immunodeficiency virus (SIV), a similar 
gene is seen in a slightly different form, including vpr as well as a duplicate, vpx. In SIV, these 
two genes have been shown to split the functions of HIV-1 vpr. In order to use SIV as a model 
for HIV-1, it must be determined which SIV gene is responsible for mediation of different 
functional effects. 
 
HIV-1 vpr has been shown to downmodulate surface markers on dendritic cells and alter 
cytokine environments in vivo.  Studies have shown that HIV-1 vpr pushes natural killer cells 
into anergy, rendering them non-functional.  Results presented in this study indicate SIV 
infection also results in these effects, but responsibility for these effects is split between SIV vpr 
and vpx. The vpx gene appears to play a role in downmodulation of surface receptors on dendritic 
cells and changes the cytokine environment within the dendritic cells. The vpr gene, however, 
appears to be responsible for decreased functionality of NK cells, leading to a non-functional 
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anergic state. These findings suggest SIV vpx and vpr cause similar effects compared to HIV-1 
vpr and, as expected, the SIV genes split the functions of their HIV-1 homolog.  
 
Statement of Public Health Relevance: HIV infection and disease is a growing epidemic and it 
has become increasingly apparent that in vitro studies are not sufficient to provide the data 
needed to create an effective vaccine. Because vaccine research cannot be performed on human 
subjects, the best mode for transition would be a shift to in vivo studies on non-human primates 
using SIV as a model for HIV-1 infection and disease. Before this can be adopted, it will be 
necessary to show HIV-1 and SIV have similar effects in vitro on immune cells and can be used 
interchangeably. 
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1.0  HIV AND SIV: AN INTRODUCTION 
1.1 HIV 
The World Health Organization currently estimates that 42 million people worldwide are 
infected with the human immunodeficiency virus (HIV) and that there are 14,000 new infections 
each day [10]. The distribution of these cases, however, is disproportionate, with most infections 
occurring in Sub-Saharan Africa and South East Asia (Table 1).  
Table 1. Regional HIV and AIDS Statistics (2007) 
There are currently an estimated 42 million HIV/AIDS cases around the world. The distribution of 
these cases is uneven and certain areas carry the bulk of the total cases around the world. Adapted 
from WHO statistics. 
 
 
Individuals history of a sexually transmitted disease, men and women who have unprotected sex 
with multiple partners, men who have sex with men, injection drug users who share needles, and 
Region Adults & Children 
Living with 
HIV/AIDS 
Adults & 
Children 
Newly Infected 
Adult 
Prevalence 
Deaths of 
Adults & Children 
Sub-Saharan Africa 22.5 million 1.7 million 5.0% 1.6 million 
North Africa & Middle 
East 
380,000 35,000 0.3% 25,000 
South and South-East 
Asia 
4 million 340,000 0.3% 270,000 
East Asia 800,000 92,000 0.1% 32,000 
Oceania 75,000 14,000 0.4% 1,200 
Latin America 1.6 million 100,000 0.5% 58,000 
Caribbean 230,000 17,000 1.0% 11,000 
Eastern Europe & 
Central Asia 
1.6 million 150,000 0.9% 55,000 
Western and Central 
Europe 
760,000 31,000 0.3% 12,000 
North America 1.3 million 46,000 0.6% 21,000 
Grand Total 33.2 million 2.5 million 0.8% 2.1 million 
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health care workers with needle stick exposure are at the greatest risk for exposure to the virus 
[11]. Additionally, the virus can be passed horizontally from mother to child during childbirth as 
well as through breastfeeding [11].  There is currently no known cure or preventative vaccine for 
HIV and the only known effective prevention of HIV transmission is abstinence from sexual 
intercourse and the use of a condom [63]. Infected individuals can, however, now live longer and 
more normal lives with the use of highly active antiretroviral therapy (HAART). This drug 
regimen targets different parts of the viral lifecycle in an effort to prevent rapid T-cell loss by 
preventing reverse transcription, integration, or maturation of the virus particle [2]. Using 
HAART during pregnancy has also helped to nearly eliminate horizontal transmission from 
mother to child during childbirth within the United States and has helped to significantly 
decrease cases in the developing world [64]. Despite these advances, more work needs to be 
done to decrease the number of new infections each year. 
 
HIV is a member of genus Lentivirus and the family Retroviridae. The virus is a 9.8 kilobase 
single stranded RNA genome, composed of nine genes coding for a different structural (gag, env, 
and pol), regulatory (tat and rev), and accessory (vif, vpr, nef, and vpu) proteins (Fig 1).  
 
Figure 1. Genomic organization of HIV-1 
Schematic depicting the organization of the HIV-1 genome, including all structural and non-
structural accessory proteins necessary for infection and replication of target cells.  
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Long terminal repeats (LTRs) flank both ends of the genome and serve as the promoter for viral 
transcription [2]. HIV-1 has an envelope, which is used to gain entry into a cell [2]. Specifically, 
the gp120 envelope protein uses the CD4 receptor CXCR4 and CCR5 co-receptors to enter a 
host cell. Upon entry, the HIV-1 genome is reverse transcribed into DNA in the cytoplasm of the 
cell [2]. Through the action of various accessory proteins, the viral DNA then enters the nucleus, 
where it can integrate into the host chromosomal DNA [2]. The virus targets a number of 
different cell types, including CD4+ T cell and macrophages, where post-infection latent 
reservoirs are established, causing both the initial asymptomatic period and an inability to fully 
rid a patient of the virus [2]. This reservoir effects a number of different cells, including dendritic 
cells (DCs) and natural killer (NK) cells, that play crucial roles in the immune response as well 
as the spread of the virus [2]. While only a small percentage of DCs become infected, many 
more are effected by the presence of virus, viral proteins and virally infected cells within the 
microenvironment [2]. These steps are depicted below by Nielsen et al (Fig. 2) [2]. 
 
Figure 2. HIV Life cycle 
Lifecycle of HIV-1, used with permission. Virus enters via virus-specific receptors CD4, 
CCR5/CXCR4. The virus then uncoats within the cytoplasm and reverse transcription of the genome 
occurs. The genome is then moved to the nucleus with the aid of accessory proteins where it then 
integrates into the host cellular DNA. Host proteins transcribe the genome into RNA, which can then 
be used for translation of viral proteins and also packaged into viral particles for release. The virus 
assembles at the cell membrane where it then buds out and matures and can then go on to infect 
other cells. 
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HIV-1 accessory proteins play important roles in the development of pathogenesis and the virus’ 
evasion of the immune system [1, 3]. Many of the accessory proteins are crucial for infection and 
deletion of these proteins results in a dead or non-infections virus [65]. 
Table 2. HIV-1 Protein Function.  
All HIV-1 proteins and their associated functions. 
 
HIV-1 Protein Function 
Vif Viral infectivity factor; RT complex stability 
Nef Negative Factor; Downregulates CD4 and MHC I expression; plays role in 
viral pathogenesis 
Gag Comprises the matrix, capsid, nucleocapsid structural proteins; p24 protein 
Pol Precursor to Protease, integrase, and reverse transcriptase 
Rev Regulator of expression; promotes nuclear import of viral RNA 
Tat Transcriptional activator; enhances gene transcription 
Vpu Down-modulates CD4 and enhances viral release 
Env Comprise the viral envelope and promote cellular attachment; gp-41 and gp-
120;  
Vpr Viral protein R; plays role in transport of pre-integration complex, apoptosis 
and transactivation of cells, as well as G2 cell cycle arrest 
 
HIV is known to infect CD4+ T-cells and kill them through viral replication [4]. This process 
directly leads to the illness known as acquired immune deficiency syndrome (AIDS) and other 
complications such as decreased ability to fight off infections. HIV can also infect other immune 
cells such as macrophages and DCs, which present antigens to CD4+ and CD8+ T-cells. This 
passage of virus leads to infection of CD4+ T-cells, which allows virus propagation. Dendritic 
cells, which typically are not infected, can also acquire live virus and present it to T-cells, 
infecting them in the process [7]. These disease pathways lead to the clinical symptoms seen in 
HIV-1 infected patients, such as increased susceptibility to opportunistic pathogens. 
 
The infection process of HIV-1 has been studied extensively, and has lead to advances such as 
HAART that allow for better viral control. Despite these advances, though, clinical responses to 
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HIV infection are still limited to treatment confining prevention efforts to public health efforts 
such as education and condoms. While the development of a universal vaccine is still only a 
distant goal, because HIV-1 is only able to infect humans, an animal model is not available for 
the study of HIV-1 infection. The current in vitro models have allowed for progress but are 
limited in application, as they only distantly mimic what actually happens during infection, 
looking at events singly and not within the context of the rest of the body and immune system. 
This limitation poses the biggest obstacle in the study of HIV-1 pathogenesis and the 
development of an effective vaccine strategy. The best and most physiologically relevant model 
we have is simian immunodeficiency virus (SIV) infection of non-human primates.  
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1.2 SIV 
Like HIV-1, SIV is also a member of genus Lentivirus and the family Retroviridae. The SIV 
genome, however, is slightly bigger at about 10.6 kilobases. The SIV RNA genome, which is 
very similar to HIV-1, also consists of structural, accessory, and regulatory genes that encode for 
all the proteins used by the virus (Fig 3). One of the biggest structural differences between HIV-
1 and SIV is in the accessory genes. HIV-1 contains vpu where many strains of SIV are missing 
this gene. A number of SIV strains instead have a duplication of vpr named vpx, where HIV-1 
does not have vpx gene (Fig 3). As with HIV, there are a number of different SIV strains, which 
infect different primate species. Each of these strains has slightly different pathogenicity and 
tropism, but many general characteristics are similar.  
 
Figure 3. Genomic Organization of SIV 
Schematic depicting the organization of the SIV genome. Depicts all of the structural and non-
structural genes in the virus. Shows difference between SIV and HIV is the deletion of Vpu and the 
addition of Vpx, which is not seen in HIV-1.  
 
This project will mainly focus on the vpx and vpr genes, specifically in the SIVsmm strain. In 
SIVsmm, vpx and vpr have a high degree of homology, so much so that it is presumed that 
SIVsmm vpx originated from a duplication event of vpr [6].  Despite this, differences in function 
between SIVsmm vpr and vpx have been documented [5]. Additionally, while vpx is packaged 
within the virion, SIV vpr is produced de novo during productive infection [7, 8]. Vpr and vpx in 
SIVsmm and other SIV strains split the functions of HIV vpr (Table 2). Specifically, the gene 
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vpx appears to play a role in infection of non-dividing cells, viral replication, and efficient 
nuclear import of the pre-integration complex, while vpr is important in cell cycle arrest [5, 9, 
10].  
 
These differences between SIV and HIV should be studied in order to better interpret the roles of 
accessory genes and their interactions with the immune system. In order to accomplish this, in 
vivo studies must be performed.  Before this can be done, however, in vitro studies must show 
that the effects of HIV-1 infection are similar to those of SIV infection. This project focused on 
this first step in developing a viable animal model for HIV-1 research. Observations made using 
HIV and HIV vpr mutants for infection were compared to the effects of SIV and SIV vpr and vpx 
mutants to determine which effects of HIV vpr were caused by SIV vpr and which were caused 
by SIV vpx. This project’s results only touch briefly on the interaction of HIV and SIV with the 
host, begining the process of understanding this interaction and possibly leading to a more 
effective model for vaccine development.  
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1.3 DENDRITIC CELLS AND HIV 
Dendritic cells (DCs) play a pivotal role in the generation of an effective immune 
response against incoming pathogens by transporting antigens from peripheral tissues to lymph 
nodes, where they are presented to circulating T-cells and B-cells, initiating T-cell and B-cell 
response [12]. The importance of DCs to the antiviral response leads many viral and bacterial 
pathogens to target DCs and T-cells [13-17]. Additionally, as part of their survival strategy, some 
microbial pathogens evade the host immune system by mimicking proteins involved in host 
defense. For example, poxviruses, cytomegalovirus, and herpesvirus encode homologue cytokine 
receptors, which can bind to the cognate cytokines and block their activities [23, 30].   
 
While many different cell types are exposed to pathogens during the initial exposure of mucosal 
membranes, HIV-1 specifically targets immature DCs, Langerhan cells, and resting T-cells, 
which then promote viral replication and dissemination [19-23]. For example, immature DCs 
may be the first leukocytes to capture HIV-1 after it has crossed a mucosal surface, thereby 
transmitting virus to nearby CD4 T cells for amplification [5, 24-26]. Irrespective of the presence 
of viral antigens in infected antigen presenting cells (APCs), the immune response eventually 
fails to control HIV-1 virus production, creating an downward spiral that reduces the ability of 
DCs to induce antiviral immunity while simultaneously facilitating virus propagation. Indeed, 
while HIV-1-induced mutations leading to cytotoxic-T-lymphocyte (CTL) escape are thought to 
be the major cause of immune failure, recent studies have shown that accumulation of immature 
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dendritic cells in the periphery, in conjunction with CTL escape, could be part of HIV-1 
progression, since these cells are then unable to effectively activate naive T-cells or B-cells [5, 
27, 28].  
 
Typically, DCs respond to pathogens by undergoing a well-regulated maturation process 
requiring the transcriptional regulation of both co-stimulatory molecules and cytokine-
chemokine genes. These genes are necessary for antigen processing, presentation, and migration 
to lymphoid organs [29, 30]. Recent studies have demonstrated that DCs infected with HIV-1 
selectively fail to undergo this maturation program, making them both incapable of activating 
lymphocytes as well as defective in interleukin-12 (IL-12) production [24, 31]. HIV-1 expresses 
a number of viral proteins that have been shown to dysregulate the host cellular immune 
response as part of immune evasive strategies. Exposure of DCs to gp120 leads to an up-
regulation of activation markers indicative of functional maturation [66]; tat inhibits antigen 
induced lymphocyte proliferation[24, 32]; the nef gene downregulates CD4 and major 
histocompatibility complex (MHC) class I molecules in T lymphocytes in order to escape CTL 
recognition [33, 34], and induces up-regulation of DC-specific ICAM-3 in DCs to facilitate viral 
spread [35]; and the Nef protein induces chemokines in primary macrophages that are thought to 
facilitate lymphocyte recruitment and activation [29, 35]. Though Tat and Nef are expressed 
early during infection, they are not packaged in the virus particle.  
 
HIV-1 Vpr is a pleiotropic protein that is known to dysregulate a number of host cellular events, 
including cell cycle arrest, apoptosis, and host gene expression, upon its expression [37, 39, 40]. 
As it is present in the virion at detectable levels, it is one of the first HIV proteins seen by host 
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cells [36]. In patients with Vpr defects, disease progression, replication, and infection are 
attenuated, indicating that Vpr plays an important role in viral pathogenesis [38]. Specifically, 
the protein is necessary for the efficient infection of non-dividing cells, such as macrophages, 
and enhances viral replication within T-cell lines and activated peripheral blood lymphocytes 
[37]. Vpr is also known to persist in free and virion associated forms in vivo, exerting its effect 
on proximal and distal cells and tissues not actually infected by the virus [39]. In studies of HIV-
1 Vpr’s effect on DCs, Vpr has been shown to selectively impair the expression of co-
stimulatory molecules and maturation markers, down-regulate the production and secretion of 
IL-12, and up-regulate IL-10, suggesting that Vpr plays a special role in altering the DC 
environment to impact maturation of these cells [41].  
 
Like HIV-1 Vpr, SIV Vpx is also packaged in the virus particle, and is necessary for infection of 
macrophages [42, 43].  This, as well SIV Vpx’s ability to promote replication and SIV Vpr’s 
ability to lead to cell cycle arrest, suggests functional similarities between the two viruses and 
their effects on immune cells and pathogenesis. While the similarities between SIV vpr and vpx 
and HIV-1 vpr are being developed, many of the specific immune effects, such as the roles of 
these genes on DC maturation, have not been studied. Our goal in this study was to determine if 
the immune modulatory attributes of HIV-1 vpr are also seen with SIV vpx and vpr, and to 
determine whether SIV vpr or vpx, plays a role in this immune dysregulation. 
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1.4 NATURAL KILLER CELLS AND HIV 
Natural killer (NK) cells are large granular lymphocytes that are critical for both innate and 
adaptive immune responses [44]. The immunologic role of NK cells has been shown in a variety 
of bacterial, fungal, and viral infections including HIV-1 [45, 46]. NK cells can lyse target cells 
by releasing cytokines, chemokines, and cytolytic granules containing perforins and granzymes 
in the absence of sensitization to antigens [47]. HIV-1 infection compromises both this innate 
and adaptive immunity and, unfortunately, antiretroviral drug treatment fails to fully restore NK 
cell function [48, 49]. In vivo studies indicate NK cells from viremic HIV-1 patients are 
defective in lysis of infected or target cells compared to aviremic or uninfected subjects [50, 51]. 
HIV-1 viral antigens have been shown to dysregulate NK cell function and its interaction with 
other accessory cells. Thus the dysregulation of NK cell phenotypes, together with compromised 
cytolytic function, likely contributes to the loss of natural immunity during HIV-1 infection [44, 
52, 53]. 
 
Structural and accessory proteins of HIV-1 are known to interact with components of both innate 
and adaptive immune systems to evade host immune surveillance [54, 55]. HIV-1 Nef is a 
potential regulator of NK cell cytotoxicity by MHC class I down regulation in infected CD4+ T 
cells [56]. HIV-1 Tat has been shown to inhibit NK cell function through inhibition of LFA-I-
mediated Ca2+ influx [57]. HIV-1 envelope also inhibits NK cell cytotoxicity and survival [58-
60]. From these studies it is evident that HIV-1 uses several of its gene products to disrupt an 
early line of defense against infection.  
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HIV-1 Vpr is associated with the virus particles, and is available to host cells prior to de novo 
synthesis and productive infection [39], suggesting that Vpr might have a role in the 
dysregulation of innate immunity and NK cell dysfunction. Results published by Majumder et al 
indicate that NK cells present in PBMC infected with HIV-1 Vpr (+) virus are defective in their 
ability to lyse NK-sensitive targets and in production of the degranulation marker, CD107a, and 
thus suggest a role for HIV-1 Vpr in compromising NK cell function and innate immunity [61]. 
 
Similar studies in SIV infected rhesus monkeys to determine if any dysregulation of NK cells 
occurs found that within infected monkeys, NK cells were impaired in their production of IFN-?, 
TNF-?, and IL-2, as well as down-regulation of NK activating molecules, NKG2C and NKG2C2 
[62]. Our study aims to show that, along with these receptor and activation molecule changes, 
SIV vpr and/or vpx also plays a role in inhibiting the functional capacity of NK cells, through 
down-regulation of degranulation markers and disruption of the subset distribution. Subset 
distribution is the number of cells that are active and able to lyse versus the number of anergic 
cells that are no longer capable of acting on infected cells. 
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1.5 SPECIFIC AIMS 
HIV-1 Vpr is shown to regulate both viral and host cellular functions thereby enhancing the viral 
replication as well as evading the host immune system. This includes inhibition of cell 
proliferation, induction of apoptosis, translocation of PIC into the nucleus of non dividing cells, 
immune evasion and host cellular dysregulation. Most of the Vpr-related functions are mediated 
by virion associated Vpr exposure during early infection similar to de novo synthesized Vpr. In 
case of SIV, Vpr has a duplication, Vpx with high homology indicating that both SIV Vpr and 
Vpx might be involved in similar host cellular events. However, Vpx is packaged as virion 
associated molecule whereas Vpr is not. Based on these we hypothesis that cellular events 
regulated by virion associated Vpr via virus uptake might be regulated by SIV Vpx, whereas 
functions regulated primarily by de novo synthesized Vpr might be mediated by SIV Vpr. The 
aims of my project are to delineate the functions of SIV Vpx and SIV Vpr using virus exposed 
and infected cell systems and mutant SIV viruses. 
 
Specific Aim 1: 
• To determine the effects of SIV Vpr and Vpx on DC maturation and cytokine production 
(adaptive immune response) 
o Differentiate between the virus exposed and unexposed cells 
o DC functional assays to determine surface marker changes in the presence of 
virus  
o  Cytokine analysis to determine changes in the key cytokines that drive the 
immune response  
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Specific Aim 2: 
• To determine the effects of SIV Vpr and Vpx on NK cell function (innate immune 
response) 
o Functional analysis of NK cells within the infected milieu  
o NK subset distribution changes in the presence of mutated virus 
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2.0  MATERIALS AND METHODS 
2.1.1 Cell culture 
Monocyte-derived dendritic cells were generated from peripheral blood mononuclear cells 
(PBMCs). Heparinized blood samples were obtained with written consent from normal, healthy 
donors. PBMCs were isolated by Ficoll-Hypaque gradient centrifugation. CD14+ monocytes 
were purified by positive selection using anti-CD14 monoclonal antibody-coated magnetic 
microbeads (Miltenyi Biotech, Auburn, CA). Purity of CD14+ cells was tested by flow cytometry 
using CD14-PE (BD-Pharmingen, San Diego, CA) and CD1a-FITC (ImmunoTech, Miami, FL) 
antibody.  Greater than 95% of isolated cells were CD14 positive (characteristic phenotype of 
myeloid derived monocytes) at day 0 of culture and 85% CD1a positive (characteristic of 
immature Dendritic Cells) at day 7 of culture.  To obtain monocyte-derived DC, CD14+ cells 
(0.5X106 cells/ml) were cultured in 60 mm culture plates in a total volume of 10 mL RPMI 
(GIBCO, Gaithersburg, MD) media containing 10% FBS, 1% L-glutamine (Cambrex, 
Walkersville, MD), 1% penicillin-streptomycin (GIBCO), 25 ng/ml IL-4 (R&D Systems, 
Minneapolis, MN) and 50 ng/ml GM-CSF (R&D Systems). Half the volume of media was 
replaced every third day with fresh media containing IL-4 and GM-CSF throughout the entire 
culture period.  
 
 16 
PBMCs isolated by Ficoll-Hypaque gradient centrifugation were cultured for 2 days in RPMI 
1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin and rIL-
2 (5 U/ml). 
 
HEK293T cells were maintained in DMEM containing 10% FBS, 1% L-glutamine (Cambrex) 
and 1% penicillin-streptomycin (GIBCO).  
 
K562 cells were maintained in RPMI containing 10% FBS, 1% L-glutamine (Cambrex) and 1% 
penicillin-streptomycin (GIBCO). 
2.1.2 Proviral Constructs 
SIV PBj WT, SIV PBj?Vpr, SIV PBj?Vpx, and SIV PBj?Vpr?Vpx proviral clones were made 
and kindly provided by Dr. Fletcher’s group by site directed mutagenesis, as described [7] (Fig 
4). Each construct was transformed into JM109 strain of E. coli bacteria and grown on agar 
plates. Colonies were then screened by gel electrophoresis and sequencing for the correct clones 
with the correct mutations in the proper positions.   
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Figure 4. SIV PBj Vpr and Vpx mutants 
Figure taken from Fletcher et al [7], used with permission, describing the construction of the mutants 
used in this study. Site directed mutagenesis was used to place stop-codons in to prevent the synthesis 
of the protein. X2 is the vpx mutant, R2 is the vpr mutant, and XR2 is the double mutant for both vpr 
and vpx. All proviral constructs were a gift from Dr. Vanessa Hirsch, NIH. Along with these mutants 
a wild-type proviral clone was also used.  
2.1.3 Virus Preparation 
SIV PBj WT, SIV PBj?Vpr, SIV PBj?Vpx, and SIV PBj?Vpr?Vpx viral constructs were 
pseudotyped with vesicular stomatitis virus (VSV-G) envelope protein, denoted as WT, ?Vpr, 
?Vpx, and ?Vpr?Vpx respectively. HEK293T cells (2x106) were co-transfected with 7.5?g of 
SIV PBj proviral construct  (SIV PBj WT, SIV PBj?Vpr, SIV PBj?Vpx, or SIV PBj?Vpr?Vpx) 
and 2.5?g VSV-Glycoprotein-Envelope (VSV-G-Env) expression plasmids by the calcium 
phosphate precipitation method. Forty-eight hours post-transfection, supernatants were collected, 
spun at 3000 rpm and filtered through a 0.4?m filter to remove cellular debris. All virus stocks 
were further concentrated by ultra centrifugation at 22,000 rpm for 1 hour at 4oC.  Virus pellets 
were resuspended in PBS and stored at –80 C for subsequent assays. Virus titer was measured 
using a p27 ELISA kit and associated protocol (Zeptometrix).  
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2.1.4 Virus Staining 
In initial experiments SIV PBj WT, SIV PBj?Vpr, SIV PBj?Vpx, and SIV PBj?Vpr?Vpx 
pseudotyped viruses were stained directly with Cy5 mono-reactive dye (Amersham). 1 mg/ml of 
virus was used for the staining reaction. Virus sample dissolved in 1mL of 0.1 M sodium 
carbonate-sodium bicarbonate buffer and then added to the dye vial. This was mixed thoroughly 
by inverting the vial. The reaction was incubated at room temperature for 30 minutes, mixing 
every 10 minutes. Labeled virus was separated from free dye through the use of a G-25 M 
Sephadex column (Amersham). The column was equilibrated with DPBS twice before adding 
the reaction mix. The reaction mix was added to the column and further DPBS was added to the 
column to allow the mix to run through the column. Two bands can be seen on the column, the 
faster moving band is the labeled virus, while the slower moving band is the free dye. The first 
band was collected, made into small aliquots and stored at -20C. Virus titer was measured by p27 
ELISA kit and associated protocol (Zeptometrix).  
2.1.5 Immunophenotypic analysis of SIV PBj virus exposed dendritic cells 
DC, after 6 days of culture with IL-4 and GM-CSF, were exposed to 100ng of SIV PBj WT, SIV 
PBj?Vpr, SIV PBj?Vpx, or SIV PBj?Vpr?Vpx virus for 48 hours, were stimulated with or 
without 1 ?g/ml lipopolysaccharide (LPS) (Sigma Aldrich) for final 24 hours. Expression of DC 
phenotypic maturation markers (CCR7, CD83, CD86, and HLADR) were detected both in 
unexposed and SIV PBj exposed cells using fluorescently conjugated monoclonal antibodies. 
The antibody concentrations used in this experiment were as per the manufacturer’s suggestions 
(CCR7: R and D cat# FAB197F, CD83: Beckman Coulter cat# PN 1M2218U, CD86: Beckman 
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Coulter cat# PN IM2729, and HLADR: BD Bioscience cat# 555813). This was followed, in 
initial experiments by permeablization of the cells using BD CytoFix/Perm solution for 20 
minutes followed by two washes (BD). Cells were incubated with 5?l of p27 antibody for 15 
minutes and then washed twice (Advanced Biotechnologies; cat# 13-113-100). A FITC labeled 
anti-strepavidin secondary antibody was incubated with the cells for another 15 minutes and then 
washed twice. Cells were then resuspended in DPBS with 3% FBS. 
2.1.6 Biotinylation of p27 antibody used in flow cytometry 
The p27 Gag protein specific antibody (Advanced Biotechnologies; cat# 13-113-100) was 
biotinylated using a 25mg/ml solution of Biotin long arm NHS (Vector Labs cat. #SP-1200) 
made in DMSO. Of this solution, 1?l (25?g) was added to a vial of antibody (100?l), and the 
tube was mixed well and incubated for 3 hours at room temperature, mixing periodically. The 
antibody was then transferred to a small dialysis cassette (Slide-A-lyzer; Pierce; 2500m.w. 
cutoff), placed in a floating rack, and dialyzed in 1L of PBS with a slow stirbar for 1 hour.  This 
was repeated with 2 fresh liters of PBS, and the last wash was overnight at 4oC. The antibody 
was then collected and stored at 4oC.  
2.1.7 Measurement of TNF-? ,  IL-12, IL-10, and IL-15 by ELISA 
Following stimulation, supernatants were collected and analyzed for the presence of TNF-? (BD 
Bioscience cat# 555212), IL-12 (BD Bioscience cat# 555183), IL-10 (BD Bioscience cat# 
555157), and IL-15 (BD Bioscience cat# 559268) using Opti-EIA ELISA assay kits according to 
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the manufacturer’s protocol. ELISA plates were developed using the TMB Substrate Reagent Set 
(BD Bioscience cat# 555214). 
2.1.8 Western Blot 
Uninfected and Cy5 labeled SIV PBj WT virus exposed DC at varying concentrations were 
washed twice with PBS and lysed in RIPA buffer containing 50mM Tris (pH 7.5), 150mM NaCl, 
1% Triton-X100, 1mM sodium orthovanadate, 10mM sodium fluoride, 1.0mM phenylmethyl-
sulfonylfluoride, 0.05% deoxycholate, 10% SDS, 0.07 trypsin inhibitor units/ml aprotinin, and 
protease inhibitors leupeptin, chymostatin, and pepstatin (1 μg/ml; Sigma). Cell lysates were 
clarified by centrifugation and total cell lysates (50?g) were separated on a SDS-PAGE gel, 
transferred, and the expression of p27 gag protein (Advanced Biotechnologies cat# 13-113-100) 
was detected. Loading was based on protein estimation prior to loading.  
 
Western Blots were also done on virus pellets to determine the reactivity of the p27 gag protein 
antibody (Advanced Biotechnologies cat# 13-113-100). The pellets were separated on a SDS-
PAGE gel, transferred, and the expression of p27 gag protein was detected. 
2.1.9 NK Cell Degranulation and Subset Distribution Assay 
To quantitate the cell surface expression of CD107a and determine the subset distribution of NK 
cells, infected PBMC (total 1X106/mL) were washed twice in PBS, and activated with K562 
target cells (PBMC: K562=1:1) in a total volume of 200μL pre-warmed culture media following 
centrifugation for 5 minutes at 1200 rpm to facilitate the contact of cells. PBMCs stimulated for 
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one hr with K562 cells were further incubated with 6?l of Golgistop (BD Bioscience, 
Mountainview, CA) at a final concentration of 6?g/ml for an additional three hrs. Cells were also 
stained with 10?L of anti-CD107a-FITC antibody for the entire duration of the incubation. Cells 
were collected and washed with PBS containing 3% FBS. Cells were then stained with an 
additional 10 ?l per tube of anti-CD107a-FITC antibody (BD Bioscience cat# 555800) as well as 
with anti-CD3-ECD antibody (Beckman Coulter cat# PN IM2705U), anti-CD16-PC5 antibody 
(BD Bioscience cat# 555408), and anti-CD56-PE antibody (Beckman Coulter cat# PN IM2073), 
for surface expression and determination of subset distribution of NK cells, for additional one 
hour in ice. Cells were washed with PBS containing 3% FBS two times and then resuspended in 
400?L of wash buffer. Cells were read by flow cytometry by gating on CD3- and CD56+ NK 
cells and those cells were then evaluated for CD107a and CD16 expression. 
 
2.1.10 Statistical analysis 
Results were analyzed using the paired student t test. A p value less than ?0.05 was considered 
statistically significant. 
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3.0  RESULTS 
3.1 THE EFFECTS OF SIV VPR AND VPX ON DC MATURATION AND 
CYTOKINE PRODUCTION 
3.1.1 Differentiating Between Virus Exposed and Unexposed Dendritic Cells 
In order to properly evaluate the effects of virus exposure, it is essential to differentiate between 
virus exposed and unexposed cells. A p27 antibody was utilized to attempt to identify DCs 
transduced with the virus. SIV PBj WT, SIV PBj?Vpr, SIV PBj?Vpx, or SIV PBj?Vpr?Vpx 
virus pellets, collected 72 hours post transfection and concentrated using high speed 
centrifugation, were examined by western blot to insure that the antibody could indeed detect 
p27 in the virus treated samples. Results from this attempt indicated that the antibody detected 
p27 in each of the virus treated cultures and not in the cultures not treated with virus, showing 
the antibody was specific and could detect p27 in cultures treated with each of the virus types 
(Fig 5).  
                      
Figure 5. p27 Staining of SIV Virus Pellet  
Western blot using anti-p27 specific antibody to detect virus particle in supernatants collected from 
transfected 293T cells. Mock trans is supernatant from 293T cells that were transfected with 
irrelevant plasmid vector control.   
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Because the antibody was effective in detecting Gag (p27) in virus treated samples, and these 
levels correlated with the levels of p27 determined in the virus pellet by the p27 ELISA kit, it 
confirmed the antibodies ability to detect the protein and we decided to use it to detect p27 
through flow cytometry. This antibody presented a possible method of differentiating between 
virus exposed and unexposed cells. The antibody was then biotinylated for use with a FITC 
fluorochrome conjugated secondary antibody for use in flow cytometry. Immature monocytes 
derived dendritic cells (iMDDC) were then exposed SIV PBj WT virus at a concentration of 
100ng of p27, as determined by p27 ELISA. The cells were then collected and stained with the 
anti-p27 primary antibody and the FITC conjugated secondary antibody at varying 
concentrations. The cells were then screened by flow cytometry to determine which 
concentration was best able to differentiate between the virus exposed and the unexposed DCs. It 
was determined that at low concentrations the antibody did not stain virus treated cells, and at 
higher concentrations the antibody bound non-specifically to the cells in both the treated and the 
untreated samples (Fig 6). This non-specific binding was not seen in the IgG control antibody but 
suggesting this was a problem with the p27 antibody specifically (Fig 6).  
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Figure 6. p27 Staining of Immature Dendritic cells 
Immature dendritic cells were exposed to virus and were then stained with varying concentrations of 
anti-p27 antibody. The stained samples were then evaluated by flow cytometry. 
 
These results suggested that there was either a problem with the use of this p27 antibody in flow 
cytometry in general or in DCs. We tested the antibody in PBMCs in order to determine the 
reason for the problem. PBMCs were used after infection with SIV PBj WT for 3, 6, and 9 days. 
Each day samples were collected and stained with differing concentrations of p27 antibody and 
analyzed by flow cytometry. It was determined that at a concentration of 5?l of antibody, it was 
possible to detect p27 in the virus exposed cells, and this was specific to the virus exposure as no 
p27 was detected in the unexposed cells (Fig 7).  
 
 
 
 
 
Figure 7. p27 Staining of PBMCs  
Human PBMCs were exposed to SIV PBj WT and were then stained with p27 antibody at differing 
concentrations to determine what concentration showed the best detection ability. 
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The percentage of p27 positive cells also increased on day 6 and day 9 suggesting an increase in 
infected cells, as would be expected (Fig 8). 
 
 
 
 
 
Figure 8. PBMCs exposed to SIV PBj WT Virus Over Time 
PBMCs were exposed to SIV WT virus over 3, 6, or 9 days and were then harvested and stained with 
5?l of anti-p27 antibody and were then evaluated by flow cytometry for changes in the number of 
p27 positive cells.  
 
This suggested that the problem was not with the p27 antibody, but instead was a problem with 
the use of this antibody in DCs, and that within DCs the antibody bound non-specifically and 
would not be useful in differentiating between virus-exposed and unexposed DCs.  
 
An alternative to p27 staining was examined. Instead of exposing cells to virus and looking for 
the cells that had picked up virus by antibody staining, the virus itself was tagged with a 
fluorochrome and this tagged virus was then used to infect the DCs. Flow cytometry was then 
used to follow the tagged virus and distinguished between cells that took up virus and those that 
did not. Initial studies were done using only SIV PBj WT virus tagged with the Cy-5 
fluorochrome, to determine whether the tagged virus was visible using flow cytometry. Dendritic 
cells were infected with increasing amounts of virus and the cells were evaluated by flow 
cytometry. The amount of tagged virus picked up by the DCs increased as the concentration of 
virus increased, as seen by the increase in MFI (Fig 9).  
17.5 0.74 
Day 3 Day 9 Day 6 
3.28 
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Figure 9. Dendritic Cells Exposed to Cy5 Labeled Virus  
Immature dendritic cells were exposed to Cy5 labeled virus for 72 hours at varying concentrations 
based on p27 ELISA measurements. Cells were collected and fixed and evaluated by flow cytometry. 
Mean fluorescence was determined by the use of FLOWJO software. 
 
This showed that, at increasing concentrations, we were able to see the virus being taken up by 
the cells and the virus was tagged appropriately. We then looked at the percent of cells positive 
for the virus, in order to see the DCs that took up virus versus those cells that did not. This was 
also done using flow cytometry and it was seen that there was actually no cell population that did 
not pick up some virus at virus concentrations typically used (Fig 10). This suggested that all 
dendritic cells are exposed to the virus, even at low concentrations. Due to these results the 
remaining experiments used unstained virus for simplicity.  
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Figure 10. Immature Dendritic Cells Exposed to Cy-5 tagged SIV PBj WT 
Immature dendritic cells exposed to APC-labeled SIV PBj WT virus at varying concentrations. 
Histograms show the percent of total cells expressing APC, suggesting uptake of or exposure to virus.  
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3.1.2 Determining Effect of SIV PBj Mutant Viruses on Dendritic Cell Surface Marker 
Expression  
We looked at important maturation markers such as CD83 and CD86, as well as migration 
marker, CCR7, which tells the DC to move to the lymph node, and HLA-DR, a control to ensure 
the up or down regulation seen was specific and not an up or down regulation of all surface 
markers. Initial studies were done comparing tagged and untagged virus to determine whether 
the changes could be seen without differentiating between cells that took up virus. Stained and 
unstained SIV PBj WT virus was used in this experiment and the cells were stained for CD83, 
CD86, and CCR7 (Fig 11-13). It was found that these results were similar to those seen with the 
unstained virus, suggesting again that all cells pick up virus, and the surface marker 
changes/differences could be seen without having to establish separate populations of cells that 
picked up virus and those that did not (Fig 11-13). The labeled and unlabeled viruses were run on 
separate machines, but the percentages were comparative suggesting the populations are 
comparable. 
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Figure 11. Comparing Labeled and Unlabeled Virus Exposed Cells for CD83 Expression 
One set of immature dendritic cells was exposed to APC tagged virus and another set of immature 
dendritic cells was exposed to untagged virus at the same concentrations. Donor was left either 
unexposed or exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. Untagged virus 
was prepared similarly but without the Cy5 label. Cells were then collected and fixed and stained for 
the maturation marker CD83. They were then evaluated by flow cytometry for expression of these 
markers. For the untagged virus, the red histograms are the IgG control, blue are the unexposed 
cells, and green are the virus-exposed cells. For the tagged virus, the red histograms are the 
unexposed cells and the blue are the virus-exposed cells. Gating was set on based on the IgG control.  
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Figure 12. Comparing Labeled and Unlabeled Virus Exposed Cells for CD86 Expression 
One set of immature dendritic cells was exposed to APC tagged virus and another set of immature 
dendritic cells was exposed to untagged virus at the same concentrations. Donor was left either 
unexposed or exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. Cells were then 
collected and fixed and stained for the maturation marker CD86. They were then evaluated by flow 
cytometry for expression of these markers. For the untagged virus, the red histograms are the IgG 
control, blue are the unexposed cells, and green are the virus-exposed cells. For the tagged virus, the 
red histograms are the unexposed cells and the blue are the virus-exposed cells. Gating was set on 
based on the IgG control. 
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Figure 13. Comparing Labeled and Unlabeled Virus Exposed Cells for CCR7 Expression 
One set of immature dendritic cells was exposed to APC tagged virus and another set of immature 
dendritic cells was exposed to untagged virus at the same concentrations. Donor was left either 
unexposed or exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. Cells were then 
collected and fixed and stained for the migration marker CCR7. They were then evaluated by flow 
cytometry for expression of these markers. For the untagged virus, the red histograms are the IgG 
control, blue are the unexposed cells, and green are the virus-exposed cells. For the tagged virus, the 
red histograms are the unexposed cells and the blue are the virus-exposed cells. Gating was set on 
based on the IgG control. 
 
Once it was determined that nearly all DCs pick up virus after exposure, we then went on to look 
at the effect of this virus exposure on the maturation of these immature DCs with unlabeled 
virus. We again looked at CD83 and CD86, as well as CCR7. The presence of these makers in 
six donors was tested by 3-color flow cytometry. Compensation was done with singly stained 
DCs from the respective donor, along with doubly stained cells to ensure that each color fell in 
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the appropriate quadrant. Each donor had an unstimulated, LPS, and/or CD40L stimulated group. 
Each donor was treated the same way with the addition of 100ng of each virus. Donor variability 
provided some differences in the response of each donor, but a representative donor, donor 4, 
shows the general trend of the response in each (Fig 14-19).  As also seen in the flow cytometric 
data, the change in the surface marker expression was specific to these maturation and migration 
markers, as HLA-DR expression remained the same regardless of treatment or stimulation. 
 
Figure 14. Representative Donor for CD83 Surface Maker Expression 
Six donors were exposed to each virus type, either SIV WT, SIV PBj?Vpr, SIV PBj?Vpx, or SIV 
PBj?Vpr?Vpx. These were then either left unstimulated or were stimulated with CD40L or LPS for 
24 hours. Cells were then collected, stained for the above surface maturation markers, and fixed. 
Cells were then evaluated by flow cytometry. This plot is representative of the 6 donors. The red 
histograms are the IgG control, blue are the unexposed cells, and green are the virus-exposed cells. 
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Figure 15. Representative Donor for CCR7 Surface Maker Expression 
Six donors were exposed to each virus type, either SIV WT, SIV PBj?Vpr, SIV PBj?Vpx, or SIV 
PBj?Vpr?Vpx. These were then either left unstimulated or were stimulated with CD40L or LPS for 
24 hours. Cells were then collected, stained for the above surface maturation markers, and fixed. 
Cells were then evaluated by flow cytometry. This plot is representative of the 6 donors. The red 
histograms are the IgG control, blue are the unexposed cells, and green are the virus-exposed cells. 
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Figure 16. Representative Donor for HLA-DR Surface Maker Expression 
Six donors were exposed to each virus type, SIV WT, SIV PBj?Vpr, SIV PBj?Vpx, or SIV 
PBj?Vpr?Vpx. These were then either left unstimulated or were stimulated with CD40L or LPS for 
24 hours. Cells were then collected, stained for the above surface maturation markers, and fixed. 
Cells were then evaluated by flow cytometry. This plot is representative of the 6 donors. The red 
histograms are the IgG control, blue are the unexposed cells, and green are the virus-exposed cells. 
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Figure 17. Representative Donor for CD86 Surface Maker Expression 
Six donors were exposed to each virus type either SIV WT, SIV PBj?Vpr, SIV PBj?Vpx, or SIV 
PBj?Vpr?Vpx. These were then either left unstimulated or were stimulated with CD40L or LPS for 
24 hours. Cells were then collected, stained for the above surface maturation markers, and fixed. 
Cells were then evaluated by flow cytometry. This plot is representative of the 6 donors. The red 
histograms are the IgG control, blue are the unexposed cells, and green are the virus-exposed cells. 
 
Along with the percent of cells we also assessed the mean fluorescence intensity, MFI, or the 
amount of each molecule present on the cell surface (Fig 18-20).  
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Figure 18. CD83 MFI Data for One Donor 
Represents the mean fluorescence intensity of CD83 for one representative donor. Each donor was 
left either unexposed or exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. Data 
was gathered by flow cytometry and software analysis by FLOWJO.  
 
Figure 19. CD86 MFI Data for One Donor 
Represents the mean fluorescence intensity of CD86 for one donor with similar results as compared 
to other donors. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, SIV 
PBj?Vpr, or SIV PBj?Vpx?Vpr. Data was gathered by flow cytometry and software analysis by 
FLOWJO. Cells were either left unstimulated, as in the first 5 bars, or stimulated with LPS, as in the 
middle 5 bars, or stimulated with CD40L. 
LPS CD40L 
LPS CD40L 
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Figure 20. CCR7 MFI Data for One Donor 
Represents mean fluorescence intensity of CCR7 for all six donors. Each donor was left either 
unexposed or exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. Data was 
gathered by flow cytometry and software analysis by FLOWJO. Cells were either left unstimulated, 
as in the first 5 bars, or stimulated with LPS, as in the middle 5 bars, or stimulated with CD40L. 
 
Each donor has great variability, but the general trends were very similar. When looking at the 
individual data for each donor (data not shown) we decided to compare the trends between the 
unstimulated samples and CD40L stimulated samples. The greatest differences could be seen 
between SIV PBj WT, and SIV PBj?Vpr or SIV PBj?Vpx (Fig 21-22). When each virus treated 
sample was compared with the other, the MFI showed a downregulation in the SIV PBj WT, and 
SIV PBj?Vpr treatments for each of the surface marker. This suggested that vpx played a role in 
the down regulation of these surface markers, as a rebound from an MFI of 650 to 850 was seen 
in CD86 and a rebound from an MFI of 65 to 75 in CD83 when vpx was deleted (Fig 20-21). 
This rebound was not seen when vpx alone was present and vpr was deleted. This same trend was 
not seen when the percent of cells expressing the markers was evaluated (Fig 14-17). 
LPS CD40L 
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Figure 21. Complied Donor CD83 MFI Data 
Represents complied donor CD83 MFI information. The horizontal line in each treatment represents 
the mean MFI. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, SIV 
PBj?Vpr, or SIV PBj?Vpx?Vpr. Each donor is symbolized by a different colored symbol. 
Significance was determined by paired student t-test. 
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Figure 22. Complied Donor CD86 MFI Data 
Represents complied donor CD86 MFI information. The horizontal line in each treatment represents 
the mean MFI. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, SIV 
PBj?Vpr, or SIV PBj?Vpx?Vpr. Each donor is symbolized by a different colored symbol. 
Significance was determined by paired student t-test. 
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This difference, seen in the absence of vpx, was also seen for the migration marker CCR7 (Fig. 
22). There was a significant increase in CCR7 on the cell surface when vpx was deleted, while 
this increase was not seen when vpr was deleted (Fig 22).  
                        
                       
Figure 23. Compiled Donor CCR7 MFI Data 
Represents complied donor CCR7 MFI information. The horizontal line in each treatment represents 
the mean MFI. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, SIV 
PBj?Vpr, or SIV PBj?Vpx?Vpr. Each donor is symbolized by a different colored symbol. 
Significance was determined by paired student t-test. 
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3.1.3 Determining Effect of SIV PBj Mutant Viruses on Dendritic Cell Cytokine 
Production 
We wanted to determine if changes in certain cytokine types that would push the immune 
response toward type 1 and type 2 response, these cytokines are typically associated with T-cells 
but in this case the response will determine the ability of the DCs to activate the T-cells and push 
them to a type 1 or type 2 response, and we wanted to determine if SIV vpr or vpx played a role 
in the change. Dendritic cells were infected with each virus type and were stimulated as 
previously described with LPS or CD40L. The supernatants were collected after stimulation and 
evaluated for the presence of various cytokines. The same donors used for the surface marker 
data, were evaluated for TNF-?, IL-10, IL-12 p-70, and IL-15 (Fig 24-26). No IL-15 was ever 
detected under any treatment or stimulation (data not shown).  
         
Figure 24. IL-10 Production in Infected Dendritic Cells 
Representative of the IL-10 levels for all 6 donors. Unexposed and virus exposed dendritic cells were 
removed and the supernatant was collected for use in an IL-10 ELISA to determine the levels of the 
cytokine after each virus and stimulation treatment. Each donor was left either unexposed or 
exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. 
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Figure 25. IL-12 Production in Infected Dendritic Cells 
Representative of the IL-12 levels for one donor. Unexposed and virus exposed dendritic cells were 
removed and the supernatant was collected for use in an IL-12 ELISA to determine the levels of the 
cytokine in each virus and stimulation treatment. Each donor was left either unexposed or exposed to 
WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. 
         
Figure 26. TNF-?  Production in Infected Dendritic Cells 
Representative of the TNF-?  levels for one donor. Unexposed and virus exposed dendritic cells were 
removed and the supernatant was collected for use in a TNF-?  ELISA to determine the levels of the 
cytokine in each virus and stimulation treatment. Each donor was left either unexposed or exposed to 
WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. 
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Donor variation was seen in the amount of each cytokine produced, but when complied, the trend 
seen was similar between donors. The trend was only seen in the CD40L stimulated treatments. 
In the unstimulated and LPS stimulated samples, there was a very large amount of variation 
between donors, including some donors that did express any readable amount of the cytokines 
with those stimulations. We therefore complied all of the results using the CD40L stimulated 
samples. There was an increase in each of the cytokines, from 1000 ng/?l to 6000 ng/?l of IL-10, 
from 19,000 ng/?l to 30,000ng/?l of IL-12, and 20,000 ng/?l to 30,000 ng/?l of TNF-?, when 
vpx was deleted (Fig 27-29). This increase was reversed upon the deletion of vpr leaving only 
vpx alone for IL-10 and IL-12, but deleting vpr did not reverse this trend in TNF-? production 
(Fig 27-29). The increase in each of the cytokines upon the deletion of vpx was statistically 
significant.  
 
Figure 27. Compiled TNF-?  Data for All Donors 
Represents complied donor TNF-?  levels detected. The horizontal line in each treatment represents 
the mean cytokine level. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, SIV 
PBj?Vpr, or SIV PBj?Vpx?Vpr. Each donor is symbolized by a different colored symbol. 
Significance was determined by paired student t-test. Donors 1 and 2 are missing from SIV PBj?Vpr 
treatment, because that virus was not available for those two donors. 
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Figure 28. Compiled IL-12 Data for All Donors 
Represents complied donor IL-12 level detected. The horizontal line in each treatment represents the 
mean cytokine level. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, SIV 
PBj?Vpr, or SIV PBj?Vpx?Vpr. Each donor is symbolized by a different colored symbol. 
Significance was determined by paired student t-test. Donors 1 and 2 are missing from SIV PBj?Vpr 
treatment, because that virus was not available for those two donors. 
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Figure 29. Compiled IL-10 Data for All Donors 
Represents complied donor IL-10 levels detected. The horizontal line in each treatment represents 
the mean cytokine level. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, SIV 
PBj?Vpr, or SIV PBj?Vpx?Vpr. Each donor is symbolized by a different colored symbol. 
Significance was determined by paired student t-test. Donors 1 and 2 are missing from SIV PBj?Vpr 
treatment, because that virus was not available for those two donors. 
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3.1.4 Functional Analysis of NK Cells in the Presence of Wild type and Mutated Virus 
We wanted to examine the effects of vpr and vpx on the functional capacity of NK cells during 
infection of bystander cells. PBMCs were collected and stimulated with IL-2 and PHA-P for 24 
hours, and then infected with SIV PBj WT, SIV PBj?Vpr, SIV PBj?Vpx, or SIV PBj?Vpr?Vpx 
virus for 4 or 6 days. Cells were collected and then screened for the presence of the 
degranulation marker CD107a on day 4 and day 6. This specific marker was chosen as a marker 
of degranulation, and when present, and shows that the cell is capable of killing a target cell and 
has full functional capacity. It was determined that during infection the functional capacity of 
NK cells is reduced and the Vpr protein plays a role in this process. CD107a levels decreased 
significantly in the presence of virus and this decrease was reversed significantly, by nearly 50%, 
when the vpr gene was deleted (Fig 30-32). When vpx was deleted, there was little change as 
compared to WT infection. This trend was seen in all three donors, despite donor variation seen. 
The trend was consistent between donors (Fig 31). This trend was also seen in the percent of 
cells expressing CD107a as well as the amount, measured by MFI, of CD107a expressed on the 
surface of those cells (Fig 32). In both cases the double mutant served to back up the results seen 
in the vpr deletion experiment, and a decrease in the expression levels was seen. 
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Figure 30. Representative Donor Analysis of CD107a Expression on NK Cells 
PBMCs were infected with 100ng of each virus for 4 or 6 days. Cells were then stimulated with K562 
cells, as stated in the methods, and stained with CD107a to assess degranulation of NK cells. Cells 
were evaluated by flow cytometry and analyzed with FLOWJO software. Gating was on CD3- 
CD56+ cells, which were then evaluated for expression of CD107a. Each donor was left either 
unexposed or exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. 
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Figure 31. Compiled Donor Data for CD107a Expression on NK Cells as Measured by MFI 
Represents complied donor CD107a levels detected on cells. The horizontal line in each treatment 
represents the mean fluorescence intensity for the cell surface CD107a. Each donor is represented by 
a different colored symbol. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, 
SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. Significance was determined by paired student t-test. 
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Figure 32. Compiled Donor Data for Percent Positive CD107a Cells  
Represents complied donor CD107a levels detected on cell surface. The horizontal line in each 
treatment represents the percent positive cell number for the surface marker on day 4 and day 6. 
Each donor is symbolized by a different colored symbol. Each donor was left either unexposed or 
exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. Significance was determined 
by paired student t-test. 
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3.1.5 NK Subset Distribution Changes in the Presence of Wild type and Mutated Virus 
Next, we wanted to determine the effects of vpr and vpx on population changes, a shift in the 
functional versus anergic populations, within the NK cells as a result of infection among 
bystander cells. Cells were screened on day 4 and day 6. Cells were evaluated by flow cytometry 
for CD16+ cells within the CD3- and CD56+ populations. Results suggested that viral infection 
changes the subset population of NK cells in the presence of virus, either wild type or mutants. 
During infection there was an increase in the CD16+, or anergic, cell population and a decrease 
in the number of CD16-, functional NK, cell subset [67]. Infection with the Vpr mutant virus 
showed a significant decrease, by nearly 42%, in the CD16+ population as compared to the Vpx 
mutant or wild type virus (Fig 33-35). This change was seen at both day 4 and day 6. This was 
also consistent between donors, despite variation in the amount of change. Both the percent of 
CD16+ cells as well as the amount of CD16+, MFI, present, showed significant changes in the 
presence of the wild type and mutant viruses (Fig. 34).   
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Figure 33. Representative Donor for CD16 Expression on NK Cells 
PBMCs were infected with 100ng of each virus for 4 or 6 days. Cells were then stimulated with K562 
cells, as stated in the methods, and stained with CD3, CD56, and CD16. Cells were evaluated by flow 
cytometry and analyzed with FLOWJO software. Gating was on CD3- CD56+ cells, which were then 
evaluated for expression of CD16. The number on the right represents the percent CD16+ and the 
number on the left represents the percent CD16-. Donors here were the same donors used in the 
previous CD107a experiment. Each donor was left either unexposed or exposed to WT, SIV 
PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. 
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Figure 34. Compiled Donor Data for CD16 Expression on NK Cells and MFI 
Represents complied donor CD16 levels detected. The horizontal line in each treatment represents 
the mean MFI for the surface marker. Each donor is symbolized by a different colored symbol. 
Significance was determined by paired student t-test. Gating was on CD3- CD56+ cells, which were 
then evaluated for expression of CD16. Donors here were the same donors used in the previous 
CD107a experiment. Each donor was left either unexposed or exposed to WT, SIV PBj?Vpx, SIV 
PBj?Vpr, or SIV PBj?Vpx?Vpr. 
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Figure 35. Compiled Donor Data for Percent Positive CD16 NK Cells 
Represents complied donor CD16 levels detected. The horizontal line in each treatment represents 
the mean fluorescence intensity for the surface marker. Each donor is symbolized by a different 
colored symbol. Significance was determined by paired student t-test. Each donor was left either 
unexposed or exposed to WT, SIV PBj?Vpx, SIV PBj?Vpr, or SIV PBj?Vpx?Vpr. 
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4.0  DISCUSSION 
4.1 THE EFFECTS OF SIV VPR AND VPX ON DC MATURATION AND 
CYTOKINE PRODUCTION 
It has become increasingly apparent that controlling the virus initially upon infection by priming 
cells from both the adaptive and innate immune systems and clearing the body of virally infected 
cells before latent cells develop is a key part of an effective immune response. The viral set 
point, or the steadiest amount of detectable viremia following the acute phase of infection, has 
been shown to correlate with that rate of disease development and death of an infected individual 
[68]. The virus, unfortunately, does everything in its power to ensure that it has the upper hand. 
Dendritic cells, one of the first responders, are rarely productively infected, but play a very large 
role in both the immune response as well as viral trafficking [69]. HIV-1 uses its accessory 
proteins to alter the functional capacity of these cells and their ability to stimulate other immune 
cells to mount a response to the infection [65]. By understanding the mechanisms through which 
this occurs, we may be better able to treat the infection early on. We wanted to ensure that the 
same dysregulatory functions seen in HIV-1 are also seen with SIV. We also wanted to 
determine if the dysregulatory functions specifically controlled by HIV-1 vpr are also controlled 
in SIV by vpr or vpx.  
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My studies indicate that many of these mechanisms for altering maturation capacity and 
migration of DCs are also present during SIV infection. In HIV-1 infection, vpr has a role in 
controlling many of these changes, and our results indicate that in the case of DC immune 
dysfunction, SIV vpx plays the predominant role in controlling this process [8]. Similar to HIV-1 
Vpr, SIV Vpx is packaged in the virion [8]. Because most DCs are not directly infected, but are 
instead exposed to virus and viral particles by uptake of the virus, without subsequent productive 
infection, it seems that vpx would be the most likely cause.  This is because vpx is present in the 
virion and does not need to be produced de novo to cause an effect.  In my experiments we were 
able to show that nearly all DCs take up virus. The more virus in the environment, the more DCs 
are able to take up virus, but even at low concentrations of virus, a large number of DCs are able 
to take up to virus. This suggests that a large number DCs would be exposed to the structural 
proteins of the virus, as well as any proteins packaged within the virion, including vpx. SIV Vpr 
would not be made until productive infection had been established and Vpr could be made de 
novo, which helps explain the lack of SIV Vpr involvement in this dysregulation. 
 
During the course of our study it became very apparent that SIV vpx played a large role in the 
dysregulation of DCs. It played a role in both inhibiting the maturation of the cells as well as 
decreasing the expression of migration markers on the surface of the cells. In our studies we 
looked at CD83 and CD86 expression in the presence of WT as well as mutant viruses, defective 
for vpr and/or vpx.  This downregulation would decrease the maturation capacity of the cells 
preventing them from being better able to activate T-cells, allowing them to begin fighting the 
infection. Through these experiments we were able to determine that SIV Vpx plays a role in 
down regulating both of these surface markers. When Vpx was deleted, the effects were 
 56 
diminished and a rebound in the surface marker was seen.  The amount of these markers 
expressed on the surface was decreased, but the number of cells expressing the markers did not 
decrease, and remained relatively the same. 
 
This same trend was witnessed with the migration marker CCR7. When this marker is expressed 
the cell is capable of migrating to lymph nodes [70]. This would allow the cells to present 
antigen to other immune cells. SIV Vpx decreased the amount of CCR7 present on the surface of 
exposed DCs. This downregulation has the possibility of preventing cells from being able to 
“warn” other immune cells and begin mounting a response. When vpx was deleted this response 
was abrogated and there was a significant increase in the amount of CCR7 on the surface of the 
cells. Similar to the effects seen on CD86 and CD83, the number cells expressing CCR7 did not 
change, but the amount of it present on the cells was the biggest indicator of change.  
 
Along with the changes seen in the ability of these DCs to mature and migrate, HIV-1 Vpr has 
also been shown to cause changes in the cytokines these exposed cells produce. Exposed cells 
are more likely to produce Th2 cytokines, like IL-10 and less likely to secrete Th1 cytokines, 
such as IL-12 and TNF-?. Altering the cytokine environment also prevents the recruitment of 
cells, such as NK cells, cytotoxic T cells, macrophages and others, that would be more likely to 
kill infected cells, preventing reinfection of other cells. These cytokines activate transcription in 
different cell types allowing them to upregulate replication of different cell types in response to 
the cytokines. Each cytokine group elicits a different response and allows different cell types to 
replicate and mature in response to an infection. This allows the virus to further establish 
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infection by recruiting cells it can infect and prevent cells that could fight off infection from 
coming into the area.  
 
During the course of our study we determined that SIV Vpx behaves similarly to HIV-1 Vpr in 
its ability to alter the cytokines secreted by exposed cells. We measured IL-12, IL-10, TNF-?, 
and IL-15. Similar changes were seen with IL-12, IL-10, and TNF-?. In the presence of Vpx, 
each cytokine was decreased, but when vpx was deleted there was a rebound in the amount of 
cytokine secreted. Based on previous studies done with HIV-1 Vpr, this response was expected 
for both IL-12 and TNF-?, but was not expected for IL-10 [41]. In previous studies, IL-10 was 
increased in the presence of HIV-1 Vpr [41]. The reason for this difference cannot be explained 
by the results alone, and little literature exists on these cytokines in relation to SIV, so more 
work would need to be done to determine the cause for this discrepancy. Soluble IL-15 was not 
able to be detected in any of these samples and was therefore not included.  
 
DCs play a large role in the initial stages of infection and HIV-1 has developed many ways of 
insuring these pivotal cells are reduced in their ability to function in the ways that would best 
allow them to help establish an effective immune response. It is important to learn how the virus 
manipulates the cellular environment and to take this information and convert it into a treatment 
strategy. The development of an animal model is key in this process, and showing that despite 
having a slightly different genomic set up, with two genes, vpr and vpx, where HIV-1 has only 
one, vpr, we see that SIV is able to function in a similar manner, with similar dysregulation of 
immune function due to these proteins. This will be an important step in that direction.  
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4.2 THE EFFECTS OF SIV VPR AND VPX ON NK CELL FUNCTION 
The involvement of the innate immune system in protection from infection has come into focus 
more in recent years. Because HIV-1 specifically targets T-cells and cells of the adaptive 
immune system, it has been the predominant theory that enhancing the adaptive immune 
response would be the key to beating the virus in the long run. In other words, the longer one’s 
T-cells and adaptive immune cells can fight, the greater one’s likelihood for resistance to 
development of disease. While this is true, prevention of infection and keeping viral levels down 
in the initial stages, hours and days, of infection is mainly determined by the innate immune 
system [70]. It has also been discovered that HIV may not infect or target innate immune cells, 
but the presence of virus and the infection of other cells within the body does pay a significant 
toll on the bystander innate immune cells. These effects then make it harder for innate immune 
cells to help in the fight against infection both against HIV as well as against opportunistic 
infections that develop as result of the loss of adaptive immune cells. HIV-1 Vpr has been shown 
to have specific roles in this dysregulation of innate cell function, in some cases, by decreasing 
the functional capacity of the innate cells, such as NK cells [70]. In my study we wanted to 
determine if these same effects are seen in SIV as well, and to determine if the SIV vpr or vpx 
genes had any part in this dysregulation. 
 
Our study shows that these same effects are seen in SIV infection as well as HIV-1, and that the 
SIV accessory gene vpr but not vpx has a role in this dysregulation. As previous studies have 
shown, SIV Vpx, is packaged within the virion, similar to HIV-1 Vpr [8]. This allows cells to be 
exposed to the protein before de novo synthesis of viral proteins takes place. Proteins present 
within the virion would likely cause effects at early time points during infection. This protein is 
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likely to affect cells that are directly targeted by the virus, or those cells that function as APCs 
and have direct contact with the virus. During the initial acute infection, when viral titers are 
high, bystander cells may be affected, but during times when viral titers are low, bystander cells 
are less likely to be affected by virion associated proteins. HIV-1 or SIV does not infect NK 
cells, but the T-cells and macrophages present in the PBMC milieu are likely to be productively 
infected [70]. This infection will produce a greater amount of virus as well as cell death 
increasing the concentration of viral proteins in the environment [65]. The presence of these viral 
products within the environment has the potential to then affect bystander cells that are not 
infected by the virus.  This phenomenon gives some insight into the ability of SIV Vpr to have a 
role in the dysregulation of these cells, while not being productively infected by these cells.  
 
During the course of our study it became apparent that NK cells are indeed affected by SIV 
infection. We were not able to distinguish the cells that were infected within these samples, but it 
is assumed based on previous studies that the T-cells and macrophages within these samples are 
the source of the productive infection. Studies were done using p27 antibody staining in PBMCs 
to show that productive infection does occur, but the specific cell types infected were not 
identified (Fig 7). It also became apparent that SIV vpr played a significant role during infection 
in the dysregulation of NK cells, while vpx did not. After 4 days of infection CD107a surface 
levels, after stimulation with K562 cells, were decreased with SIV WT infection. The decrease 
was similar when vpx was deleted and only SIV vpr was present. This down-regulation was 
completely eliminated when vpr was deleted and a rebound to near that of the untreated sample 
was seen. This suggests that vpr plays a greater role than vpx in this down-regulation.  
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We then assessed the subset distribution of NK cells. There are functional and non-functional 
subsets of NK cells. Those cells that are CD3-, CD56+ and CD16- are the functional subset [67]. 
Those cells that are CD3-, CD56+ and CD16+ are NK cells that have been pushed into anergy 
and are no longer functional cells [67]. They are not dead and have not yet gone through 
apoptosis, but they no longer are able to perform any of their killing functions, or any other 
function. It is possible that this change in subsets is why these cells are not producing the 
degranulation markers. We looked at the subsets in the presence of virus after 4 and 6 days.  
Cells were stimulated with K562 cells and were then stained for CD3, CD56, and CD16. It 
became apparent that even after 4 days, there was indeed a shift in the subset distribution of the 
NK cells. During SIV WT infection there was a shift to a CD16+, or anergic, population. This 
suggests that productive infection does play a role in the dysregulation of NK cells. When SIV 
vpx was deleted, there was little change in the percent of cells expressing the marker or the 
amount of CD16 on the cell surface, or MFI. When vpr was deleted, however, there was a 
significant decrease in the percent CD16 positive and MFI of the marker on the cell surface. This 
suggests that SIV vpr does indeed play a role, not only in dysregulating the functional capacity 
of NK cells, but also pushes them into anergy, rendering them useless and completely non-
functional.  
 
As previously stated, NK cells are not infected by HIV-1 or SIV. This means that the infection of 
other cells in the PMBC milieu is the main avenue for the dysregulation of these particular cells. 
The fact that SIV Vpr is also the protein that is causing the functional and subset changes 
supports this argument. SIV Vpr is only present during infection, and would only be able to 
cause these effects if infected cells were making it during viral replication and transcription. 
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Despite the fact that Vpx is required for infection of non-dividing cells like macrophages, and 
that it is also known to help with the transport of viral DNA to the nucleus, infection in T-cells 
and other bystander cells still occurs and deleting this gene still allows for the dysregulation of 
NK cells with little change from that of SIV WT infection.  
 
SIV infection can be used as a model of HIV-1 infection, and despite a different genomic 
composition, the proteins produced have analogous functions. The HIV-1 vpr gene has been 
shown to have specific roles in the dysregulation of NK cells and the SIV vpr and vpx genes, 
specifically SIV vpr in this case, behave in a similar manner. This information can be used to do 
more studies to determine the specific mechanism of this interaction, and to then find ways of 
either eliminating this interaction, or decreasing it to allow these immune cells to eliminate the 
virus early and prevent reinfection and disease.  
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4.3 PROPOSED EFFECTS OF SIV VPR AND VPX ON INNATE AND ADAPATIVE 
IMMUNITY 
The specific actions of these proteins remains to be studied, but we have determined that the SIV 
Vpr and Vpx proteins do behave in a similar manner to that of HIV-1 Vpr. These two proteins 
split the functions of the one HIV-1 protein, but same end function is seen, dysregulation of the 
immune system. This dysregulation is seen in both arms of the immune system, adaptive and 
innate. The virus infects macrophages in the periphery and is picked up by DCs. These DCs are 
susceptible to the virion-associated proteins carried by the virus. The cells take the virus particles 
to the lymph nodes, and pass them to susceptible T-cells, which subsequently become infected 
with the virus. The T-cells produce virus, which is then picked up by more DCs. The virion-
associated proteins, such as Vpx, cause a downregulation of surface maturation markers and 
migration markers (Fig 36). This down regulation makes it harder for these cells to appropriately 
activate naive T-cells and B-cells to combat the growing infection. While this is happening, the 
infected T-cells are also dying and releasing viral proteins into the cellular environment. This 
release of proteins affects other cells that may not be infected within the environment, including 
NK cells. These cells are affected by SIV Vpr protein, which causes many cells to loose 
degranulation markers from the surface, and to also be pushed into an anergic state (Fig 36). This 
decreases the number of functioning NK cells, decreasing the number of cells capable of fighting 
off the growing infection even further. The combination of these two events, as a result of the 
affect of these two proteins appears to play possibly significant role in the ability of the virus to 
gain the upper hand during the course of the infection.  
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Figure 36. Combined Effect of SIV Vpr and Vpx on Innate and Adaptive Immunity 
This is a schematic representation of the affect of SIV Vpr and Vpx on the two arms of the immune 
system. The red sun shaped objects are the SIV virus particles, the blue dots are Vpx protein 
particles, and the brown dots are Vpr protein particles. 
 
This study has shown a number of similarities between HIV-1 Vpr and SIV Vpr and Vpx. These 
proteins, in conjunction with other viral proteins, dysregulate the immune system so effectively, 
that they give the virus the upper hand in may instances. If we could target these proteins 
specifically early on during infection, we may be able to stop the infection of non-dividing cells 
such as macrophages, which can serve as a reservoir for the virus. We may also be able to 
prevent the dysregulation of important immune cells such as NK cells, which have proven to be 
crucial in fighting off HIV infection, as well as opportunistic infections during AIDS. If these 
proteins can be targeted, and rendered inactive or incapable of completing their dysregulatory 
functions, we may finally be able to turn the tables on this pandemic disease.  
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5.0  FUTURE DIRECTIONS 
The findings we have presented here have offered a key glimpse into the interplay between SIV 
and DCs. These results offer a starting point to further experimentation in the area. It will be 
necessary to conduct further experiments to verify these results, as well as expand upon them.  
 
One of the biggest obstacles has been the lack of reagents for use in SIV research. We were not 
able to verify that the viruses expressed the correct proteins and didn’t express proteins they 
were intended not to. This would best be done through western blotting, but the appropriate 
antibodies for these proteins were not accessible.  
 
RT PCR analysis could be done to verify much of the data collected on the expression of surface 
markers. This same technique could be used to determine if the changes in the cytokine 
expression are a result of decreased RNA or if it is simply the amount protein released. It is also 
necessary to determine why this disconnect exists in the expression of IL-10 in the presence of 
SIV. 
 
The NK data gives some insight into the relationship between SIV vpr and the dysregulation of 
NK cells during SIV infection. Other experiments need to be done to ensure that this 
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dysregulation is truly a result of infection such as looking for evidence of infection by perhaps 
testing for p27 antibodies within the supernatant at each time point.  
 
Along with testing for changes in subset populations, apoptosis should also be looked at. HIV-1 
vpr has been known to induce apoptosis in cells and it is possible that this is also occurring in the 
NK cell population as well as the shift to anergy.  
 
Tests can also be done to verify the decrease in the CD107a expression or the functional capacity 
of these cells such as a chromium release assay. LDH assays could also be used but during our 
experiment this assay was used and the results were not consistent or reliable. Chromium release 
may be a better choice to test the functional capacity of these cells.  
 
Other groups have also looked at cytokine expression and receptor expression when looking at 
NK cells and their functional capacity during infection. It would be good to look at the effects of 
virus on these aspects as well, to determine if SIV vpr has roles in other areas of NK 
dysregulation, or if other proteins cause these aspects.  
 
We have shown that SIV does cause changes in the NK cell population, but these many not be 
the only changes and these changes must be confirmed by other techniques. 
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